Weight loss drug is not taking easy way out

Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
GLP-1 weight loss drugs - such as Wegovy and Mounjaro - may reduce risk of conditions including Alzheimer’s disease and ...
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
The skyrocketing popularity of weight-loss drugs like Wegovy, one of a class of drugs called GLP-1s, is fast becoming a state ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
There are several potential challengers to Novo Nordisk and Eli Lilly’s obesity drugs, and Jefferies analysts see one as ...